Capital International Sarl Cuts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Capital International Sarl cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 15.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,405 shares of the biopharmaceutical company's stock after selling 15,580 shares during the quarter. Capital International Sarl's holdings in Gilead Sciences were worth $8,074,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Westside Investment Management Inc. lifted its stake in shares of Gilead Sciences by 3.5% in the 3rd quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company's stock valued at $2,249,000 after purchasing an additional 917 shares during the period. SkyView Investment Advisors LLC lifted its holdings in Gilead Sciences by 5.4% during the 3rd quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company's stock worth $711,000 after buying an additional 435 shares during the last quarter. Pine Valley Investments Ltd Liability Co purchased a new stake in Gilead Sciences in the 3rd quarter valued at $209,000. World Investment Advisors LLC lifted its position in Gilead Sciences by 33.6% in the third quarter. World Investment Advisors LLC now owns 25,999 shares of the biopharmaceutical company's stock valued at $2,180,000 after purchasing an additional 6,535 shares during the period. Finally, Arvest Bank Trust Division acquired a new position in Gilead Sciences during the third quarter worth about $9,661,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analysts Set New Price Targets

GILD has been the subject of several recent research reports. Piper Sandler increased their price target on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. The Goldman Sachs Group lifted their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Oppenheimer increased their target price on Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a research note on Tuesday, March 4th. BMO Capital Markets upped their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. Finally, Royal Bank of Canada boosted their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 12th. Ten research analysts have rated the stock with a hold rating, sixteen have given a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $106.92.

Gilead Sciences Stock Down 0.2 %

GILD traded down $0.25 during trading on Wednesday, hitting $105.26. 3,054,190 shares of the company's stock were exchanged, compared to its average volume of 8,822,298. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The stock has a market cap of $131.07 billion, a P/E ratio of 284.49, a PEG ratio of 0.71 and a beta of 0.32. The business's 50 day moving average is $109.17 and its two-hundred day moving average is $97.82. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were issued a $0.79 dividend. The ex-dividend date of this dividend was Friday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 3.00%. Gilead Sciences's payout ratio is currently 854.05%.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total transaction of $266,000.00. Following the completion of the transaction, the chief financial officer now directly owns 168,174 shares in the company, valued at approximately $17,893,713.60. This represents a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have sold 302,785 shares of company stock valued at $30,540,875. Insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.